All ATC classes · L

L04 Immunosuppressants Agentes inmunosupresores 免疫抑制剂 免疫抑制劑 L2

Source: Wikidata · CC0 1.0 Fuente: Wikipedia · CC BY-SA 4.0 来源：维基百科 · CC BY-SA 4.0 來源：維基百科（中文轉繁體） · CC BY-SA 4.0 (derived zh-Hant)

ATC level L2 · Search this class · Consumer categories

Child classes

Active ingredients in this class

139 active ingredients 139 principios activos 139 个活性成分 139 個有效成分

The market codes after a status are the markets where that status is recorded (same codes as the product tables). An ingredient can be on sale in one market and withdrawn in another; that is a record fact, not a safety judgement.

Show all 139 (currently showing 80) Mostrar los 139 (ahora se muestran 80) 显示全部 139 个（当前显示前 80 个） 顯示全部 139 個（目前顯示前 80 個）
  • Daclizumab Beta L04AC01withdrawnEUdiscontinuedCA
  • Danicopan L04AJ09activeUS·GB·CA·SG·ES·TW·EUunknownAU·HK
  • Darvadstrocel L04AX08withdrawnES·EUactiveGB
  • Deucravacitinib L04AF07activeUS·GB·CA·AU·SG·ES·MX·TW·EUunknownAU·HK
  • Dimethyl L04AX07Salt form: Dimethyl FumaratewithdrawnES·EUdiscontinuedCA·ESactiveUS·GB·CA·AU·SG·ES·TW·EUunknownAU·HK
  • Diroximel L04AX09Salt form: Diroximel FumarateactiveUS·GB·AU·ES·MX·EUunknownAU
  • Efalizumab L04AG02withdrawnEUdiscontinuedCAactiveGBunknownMX
  • Efgartigimod Alfa L04AL01discontinuedESactiveUS·GB·CA·SG·ES·EUunknownAU
  • Emapalumab L04AA39activeUSunknownEU
  • Espesolimab L04AC22activeES
  • Etanercept L04AB01withdrawnMXdiscontinuedCA·MXactiveUS·GB·CA·AU·SG·ES·TW·EUunknownAU·MX·HK·EU
  • Etrasimod L04AE05activeUS·GB·CA·AU·SG·ES·EUunknownAU·HK
  • Filgotinib L04AF04discontinuedESactiveGB·SG·ES·TW·EU
  • Fumarato De Tegomil L04AX10discontinuedES
  • Guselkumab L04AC16discontinuedMXactiveUS·GB·CA·AU·SG·ES·MX·TW·EUunknownAU·HK
  • Icotrokinra Containing Product L04AC28discontinuedES
  • Imlifidasa L04AA41activeES
  • Imlifidase L04AA41activeGB·EUunknownAU
  • Inebilizumab L04AG10activeUS·CA·ES·TW·EUunknownAU
  • Infliximab L04AB02withdrawnES·EUdiscontinuedCA·ES·MXactiveUS·GB·CA·AU·SG·ES·MX·TW·EUunknownAU·HK
  • Inmunoglobulina Antitimocítica De Conejo L04AA04activeES
  • Iptacopan L04AJ08activeUS·GB·CA·AU·SG·ES·TW·EUunknownAU·HK
  • Ixekizumab L04AC13discontinuedMXactiveUS·GB·CA·AU·SG·ES·TW·EUunknownAU·HK
  • Lymphocyte Immunoglobulin Anti-Thymocyte Globulin L04AA03discontinuedCAactiveCA
  • Mirikizumab L04AC24discontinuedESactiveUS·GB·CA·ES·MX·TW·EUunknownAU
  • Muromonab-Cd3 L04AG01discontinuedCAactiveGB
  • Mycophenolic Acid L04AA06withdrawnMXdiscontinuedCA·MXactiveUS·GB·CA·ES·MXunknownAU·MX·HK
  • Natalizumab L04AG03activeUS·GB·CA·AU·SG·ES·MX·TW·EUunknownAU·HK·EU
  • Nerandomilast L04AA61discontinuedESactiveUS·GB·CA·TW·EU
  • Nipocalimab L04AL03discontinuedESactiveUS·GB·CA·EU
  • Ocrelizumab L04AG08discontinuedES·MXactiveUS·GB·CA·AU·SG·ES·MX·EUunknownAU·HK
  • Ozanimod L04AA38 L04AE02Salt form: Ozanimod HydrochlorideactiveUS·GB·CA·AU·ES·TW·EUunknownAU·HK
  • Pegcetacoplan L04AJ03activeUS·GB·CA·AU·ES·EUunknownAU·EU
  • Ponesimod L04AE04activeUS·GB·CA·ES·EU
  • Pozelimab L04AJ11activeUS
  • Ravulizumab L04AJ02discontinuedCAactiveUS·GB·CA·AU·SG·ES·TW·EUunknownAU·HK
  • Remestemcel-L L04AXactiveCA
  • Remibrutinib L04AA60discontinuedESactiveUS·GB·CA·TW·EUunknownAU·HK
  • Rilonacept L04AC04withdrawnEUactiveUS
  • Risankizumab L04AC18discontinuedCA·ES·MXactiveUS·GB·CA·AU·SG·ES·TW·EUunknownAU·HK
  • Ritlecitinib Tosylate L04AF08
  • Rozanolixizumab L04AL02activeUS·GB·CA·AU·ES·TW·EUunknownAU·HK
  • Sarilumab L04AC14discontinuedCA·ESactiveUS·GB·CA·ES·EUunknownHK
  • Satralizumab L04AC19activeUS·GB·CA·SG·ES·TW·EUunknownAU·HK
  • Siponimod L04AE03discontinuedESactiveUS·GB·CA·AU·SG·ES·MX·TW·EUunknownHK
  • Spesolimab L04AC22activeUS·GB·CA·SG·TW·EUunknownAU·HK
  • Sutimlimab L04AJ04activeUS·ES·EU
  • Talidomida L04AX02discontinuedES·MXactiveESunknownMX
  • Teprotumumab L04AG13discontinuedESactiveUS·GB·CA·SG·TW·EUunknownAU·HK
  • Tildrakizumab L04AC17discontinuedESactiveUS·GB·CA·AU·SG·ES·MX·TW·EUunknownAU·HK
  • Tocilizumab L04AC07discontinuedES·MXactiveUS·GB·CA·AU·SG·ES·TW·EUunknownAU·MX·HK
  • Tolebrutinib L04AA62discontinuedESactiveEUunknownAU
  • Ublituximab L04AG14activeUS·GB·AU·ES·EUunknownAU
  • Upadacitinib L04AF03discontinuedES·MXactiveUS·GB·CA·AU·SG·ES·TW·EUunknownAU·HK
  • Ustekinumab L04AC05withdrawnES·EUdiscontinuedES·MXactiveUS·GB·CA·AU·SG·ES·MX·TW·EUunknownAU·MX·HK
  • Vedolizumab L04AG05discontinuedES·MXactiveUS·GB·CA·AU·SG·ES·MX·TW·EUunknownAU·HK
  • Vilobelimab L04AJ10activeUS·EU
  • Voclosporin L04AD03activeUS·GB·ES·EUunknownEU
  • Zilucoplan L04AJ06discontinuedESactiveUS·GB·CA·AU·ES·TW·EU
Class names are editorial translations or come from Wikipedia (CC BY-SA 4.0) / Wikidata (CC0); each ATC page lists the exact source, licence and link for every language. Only the ATC code and the WHO hierarchy are authoritative.
Notes & licences
Status badges summarise the product records held for each ingredient (active / discontinued / withdrawn / unknown), and the market codes after each badge show where that status is recorded. Only some registers publish a status column: CA, ES and MX do; AU and HK have no status column and are recorded as unknown; CN, US, GB, TW and SG records are on the register and marked active.
Class and category names are editorial or AI-assisted translations; only the ATC code and the WHO hierarchy are authoritative.
ATC codes and hierarchy reference the WHO Collaborating Centre for Drug Statistics Methodology ATC/DDD Index (copyright WHOCC; the index itself is not reproduced). Ingredient/strength facts come from the regulator records listed on About.